🇺🇸 FDA
Patent

US 10227610

Methods and compositions for enhancing nuclease-mediated gene disruption

granted A61KA61K31/502A61K31/5377

Quick answer

US patent 10227610 (Methods and compositions for enhancing nuclease-mediated gene disruption) held by Sangamo Therapeutics, Inc. expires Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sangamo Therapeutics, Inc.
Grant date
Tue Mar 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/502, A61K31/5377, A61P, A61P43/00